{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:23:45Z","timestamp":1790195025947,"version":"4.1.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006975","name":"Indiana Clinical and Translational Sciences Institute","doi-asserted-by":"publisher","award":["UL1TR002529"],"award-info":[{"award-number":["UL1TR002529"]}],"id":[{"id":"10.13039\/100006975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"NHLBI Division of Intramural Research","doi-asserted-by":"publisher","award":["R01HL153114"],"award-info":[{"award-number":["R01HL153114"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Heart failure (HF) with reduced ejection fraction (HFrEF) is a risk factor for drug-induced QT interval prolongation. It is unknown if HF with preserved ejection fraction (HFpEF) is also associated with an increased risk. Dofetilide and sotalol are potent QT interval-prolonging agents that are frequently used in patients with HFpEF, in whom atrial fibrillation is a common comorbidity. We tested the hypothesis that the risk of QT interval prolongation associated with dofetilide and sotalol is increased in patients with HFpEF. We conducted a retrospective cohort study conducted using electronic health records from the Indiana Network for Patient Care (January 31, 2010 \u2013May 3, 2021). After removing patients with overlapping diagnoses of HFpEF and HFrEF, no diagnosis code, and absence of QT interval records, we identified patients taking dofetilide or sotalol among three groups: HFrEF (n = 138), HFpEF (n = 109), and no HF (n = 729). QT prolongation was defined as heart rate-corrected QT (QTc) &gt; 500 ms during dofetilide\/sotalol therapy. Unadjusted odds ratios (OR) for QT prolongation were determined by univariate analysis. Adjusted ORs were determined by generalized estimating equations (GEE) with logit link to account for an individual cluster with different times of hospitalization and covariates. QTc prolongation associated with dofetilide or sotalol occurred in 53.2%, 71.7% and 30.0% of patients with HFpEF, HFrEF, and patients with no HF, respectively. After adjusting for age, sex, race, serum potassium and magnesium concentrations, kidney function, concomitant drug therapy, and comorbid conditions, the adjusted odds of QTc prolongation were significantly higher in patients with HFpEF [OR = 1.98 (95% CI 1.17\u20133.33)], and in those with HFrEF [OR = 5.23, (3.15\u20138.67)], compared to those with no evidence of HF. The odds of QT prolongation among inpatients receiving dofetilide or sotalol were increased in patients with HFpEF and HFrEF compared to those who did not have HF.<\/jats:p>","DOI":"10.1371\/journal.pone.0308999","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T17:36:46Z","timestamp":1724089006000},"page":"e0308999","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Drug-induced QT interval prolongation in patients with heart failure with preserved ejection fraction"],"prefix":"10.1371","volume":"19","author":[{"given":"Chien-Yu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Overholser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Sowinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8517-5680","authenticated-orcid":true,"given":"Heather A.","family":"Jaynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2117-9463","authenticated-orcid":true,"given":"James E.","family":"Tisdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"pone.0308999.ref001","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jacc.2015.12.063","article-title":"Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes","volume":"67","author":"PJ Schwartz","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"pone.0308999.ref002","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1161\/CIR.0000000000000905","article-title":"Drug-induced arrhythmias: A Scientific Statement From the American Heart Association","volume":"142","author":"JE Tisdale","year":"2020","journal-title":"Circulation"},{"key":"pone.0308999.ref003","author":"RL Woosley","journal-title":"QTdrugs List"},{"key":"pone.0308999.ref004","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","article-title":"Development and validation of a risk score to predict QT interval prolongation in hospitalized patients","volume":"6","author":"JE Tisdale","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"pone.0308999.ref005","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJM199909163411201","article-title":"Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group","volume":"341","author":"C Torp-Pedersen","year":"1999","journal-title":"N Engl J Med"},{"key":"pone.0308999.ref006","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1161\/01.CIR.102.19.2385","article-title":"Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.","volume":"102","author":"S Singh","year":"2000","journal-title":"Circulation"},{"key":"pone.0308999.ref007","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/0735-1097(96)00121-0","article-title":"Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study","volume":"28","author":"KA Ellenbogen","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"pone.0308999.ref008","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1161\/01.CIR.96.12.4298","article-title":"Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy","volume":"96","author":"BS Stambler","year":"1997","journal-title":"Circulation"},{"key":"pone.0308999.ref009","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(98)00078-3","article-title":"Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation","volume":"31","author":"AS Volgman","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"pone.0308999.ref010","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1161\/01.CIR.94.7.1613","article-title":"Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation","volume":"94","author":"BS Stambler","year":"1996","journal-title":"Circulation"},{"key":"pone.0308999.ref011","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0002-9149(97)00395-0","article-title":"Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function.","volume":"80","author":"BS Stambler","year":"1997","journal-title":"Am J Cardiol"},{"key":"pone.0308999.ref012","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1161\/01.CIR.94.10.2535","article-title":"Sex difference in risk of torsade de pointes with d, l-sotalol","volume":"94","author":"MH Lehmann","year":"1996","journal-title":"Circulation"},{"key":"pone.0308999.ref013","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1177\/0091270011416939","article-title":"Enhanced sensitivity to drug\u2010induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction","volume":"52","author":"JE Tisdale","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"pone.0308999.ref014","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation; a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"JA Joglar","year":"2024","journal-title":"Circulation"},{"key":"pone.0308999.ref015","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cjca.2020.09.001","article-title":"The 2020 Canadian Cardiovascular Society\/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation","volume":"36","author":"JG Andrade","year":"2020","journal-title":"Can J Cardiol"},{"key":"pone.0308999.ref016","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.","volume":"42","author":"G Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"pone.0308999.ref017","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"PA Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"pone.0308999.ref018","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.amjcard.2011.07.050","article-title":"Usefulness of electrocardiographic QT interval to predict left ventricular diastolic dysfunction.","volume":"108","author":"JE Wilcox","year":"2011","journal-title":"Am J Cardiol"},{"issue":"2","key":"pone.0308999.ref019","doi-asserted-by":"crossref","first-page":"e007757","DOI":"10.1161\/CIRCEP.119.007757","article-title":"Importance of diastolic function for the prediction of arrhythmic death: a prospective, observer-blinded, long-term study.","volume":"13","author":"T Pezawas","year":"2020","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"8","key":"pone.0308999.ref020","doi-asserted-by":"crossref","first-page":"e006452","DOI":"10.1161\/CIRCEP.118.006452","article-title":"Ventricular arrhythmias underlie sudden death in rats with heart failure and preserved ejection fraction","volume":"11","author":"JH Cho","year":"2018","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"pone.0308999.ref021","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1161\/CIRCULATIONAHA.117.028202","article-title":"Delayed repolarization underlies ventricular arrhythmias in rats with heart failure and preserved ejection fraction","volume":"136","author":"JH Cho","year":"2017","journal-title":"Circulation"},{"key":"pone.0308999.ref022","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.cardfail.2020.06.008","article-title":"Enhanced response to drug-induced QT interval lengthening in patients with heart failure with preserved ejection fraction","volume":"26","author":"JE Tisdale","year":"2020","journal-title":"J Card Fail"},{"key":"pone.0308999.ref023","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.113.001475","article-title":"Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study","volume":"128","author":"R Zakeri","year":"2013","journal-title":"Circulation"},{"key":"pone.0308999.ref024","article-title":"Tikosyn\u00ae prescribing information","year":"2014","journal-title":"Pfizer Laboratories"},{"key":"pone.0308999.ref025","article-title":"Betapace\u00ae prescribing information","year":"2018","journal-title":"Covis Pharma"},{"key":"pone.0308999.ref026","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1377\/hlthaff.24.5.1214","article-title":"The Indiana network for patient care: a working local health information infrastrutcture. An example of a working infrastructure collaboration that links data from five health systems and hundreds of millions of entries","volume":"24","author":"CJ McDonald","year":"2005","journal-title":"Health Aff."},{"issue":"10","key":"pone.0308999.ref027","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of onservational studies in epidemiology (STROBE): explanation and elaboration.","volume":"4","author":"JP Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"key":"pone.0308999.ref028","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.amjcard.2007.04.020","article-title":"Risk factors and predictors of torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving dofetilide.","volume":"100","author":"HS Pedersen","year":"2007","journal-title":"Am J Cardiol."},{"key":"pone.0308999.ref029","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ehj.2004.04.015","article-title":"Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial","volume":"25","author":"T Fetsch","year":"2004","journal-title":"Eur Heart J"},{"key":"pone.0308999.ref030","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/1074248420921740","article-title":"Assessment of sotalol and dofetilide dosing at a large academic medical center","volume":"25","author":"C Ting","year":"2020","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"pone.0308999.ref031","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijcard.2018.06.066","article-title":"Efficacy and adverse effects of sotalol in adults with congenital heart disease","volume":"274","author":"BM Moore","year":"2019","journal-title":"Int J Cardiol"},{"issue":"3","key":"pone.0308999.ref032","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.4022\/jafib.2047","article-title":"Safety of twice daily sotalol in patients with renal impairment: A single center, retrospective review.","volume":"11","author":"A Rabatin","year":"2018","journal-title":"J Atr Fibrillation"},{"key":"pone.0308999.ref033","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/pace.12586","article-title":"Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation","volume":"38","author":"K Agusala","year":"2015","journal-title":"Pacing Clin Electrophysiol"},{"key":"pone.0308999.ref034","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/FJC.0000000000000610","article-title":"Dofetilide-associated QT prolongation: total body weight versus adjusted or ideal body weight for dosing","volume":"72","author":"SY Wang","year":"2018","journal-title":"J Cardiovasc Pharmacol"},{"key":"pone.0308999.ref035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.14740\/cr473w","article-title":"Scoring system based on electrocardiogram features to predict the type of heart failure in patients with chronic heart failure","volume":"7","author":"PB Hendry","year":"2016","journal-title":"Cardiol Res"},{"issue":"7","key":"pone.0308999.ref036","doi-asserted-by":"crossref","first-page":"e0254641","DOI":"10.1371\/journal.pone.0254641","article-title":"Delayed repolarization and ventricular tachycardia in patients with heart failure and preserved ejection fraction","volume":"16","author":"JH Cho","year":"2021","journal-title":"PLoS ONE"},{"key":"pone.0308999.ref037","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/jce.15012","article-title":"Limited duration of antiarrhythmic drug use for newly diagnosed atrial fibrillation in a nationwide population under age 65","volume":"32","author":"RN D\u2019Angelo","year":"2021","journal-title":"J Cardiovasc Electrophysiol"},{"key":"pone.0308999.ref038","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1161\/CIRCULATIONAHA.119.044109","article-title":"Trends in antiarrhythmic drug use among patients in the United States between 2004 and 2016","volume":"141","author":"TM Markman","year":"2020","journal-title":"Circulation"},{"key":"pone.0308999.ref039","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/CIRCEP.114.002339","article-title":"Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter.","volume":"8","author":"JM Abraham","year":"2015","journal-title":"Circ Arrhythm Electrophysiol."},{"issue":"1","key":"pone.0308999.ref040","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s43856-023-00315-8","article-title":"Efficacy and safety of dofetilide and sotalol in patients with hypertrophic cardiomyopathy.","volume":"3","author":"C Chen","year":"2023","journal-title":"Commun Med."},{"key":"pone.0308999.ref041","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1161\/01.CIR.102.19.2385","article-title":"Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter. The Symptomatic Atrial Fibrillation Investigative Resarch on Dofetilide (SAFIRE-D) study.","volume":"102","author":"S Singh","year":"2000","journal-title":"Circulation"},{"issue":"7","key":"pone.0308999.ref042","doi-asserted-by":"crossref","first-page":"e008168","DOI":"10.1161\/CIRCEP.119.008168","article-title":"Clinical outcomes and characteristics with dofetilide in atrial fibrillation patients considered for implantable cardioverter-defibrillator.","volume":"13","author":"RJ Koene","year":"2020","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"pone.0308999.ref043","doi-asserted-by":"crossref","first-page":"10742484231224536","DOI":"10.1177\/10742484231224536","article-title":"Assessment of dofetilide or sotalol tolerability in the elderly","volume":"29","author":"N Yagnala","year":"2024","journal-title":"J Cardiovasc Pharmacol Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0308999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T17:37:04Z","timestamp":1724089024000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0308999"}},"subtitle":[],"editor":[{"given":"Elena G.","family":"Tolkacheva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0308999","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]}}}